Tag Archives: Adults

FDA Approves Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Acquired Blepharoptosis (Droopy Eyelid) in Adults

FDA Approves Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Acquired Blepharoptosis (Droopy Eyelid) in Adults Print this page BRIDGEWATER, N.J, July 09, 2020 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Upneeq (oxymetazoline hydrochloride ophthalmic… Read More »

Adults With ADHD Three Times As Likely to Develop Dementia

Researchers report that ADHD adults, those adults who are suffering from attention deficit and hyperactivity disorder, are over 3 times as more likely to get a common type of degenerative dementia compared to those not having ADHD.1✅ JOURNAL REFERENCEDOI: 10.1111/j.1468-1331.2010.03064.x The researchers established the association in a study of 360 subjects having degenerative dementia and… Read More »

FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma

FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma Print this page WILMINGTON, Del.–(BUSINESS WIRE)–Apr. 17, 2020– Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously treated,… Read More »

FDA Approves Sevenfact (coagulation factor VIIa [recombinant]-jncw) for Adults and Adolescents with Hemophilia A or B and Inhibitors

FDA Approves Sevenfact (coagulation factor VIIa [recombinant]-jncw) for Adults and Adolescents with Hemophilia A or B and Inhibitors Print this page April 01, 2020 — The U.S. Food and Drug Administration today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age… Read More »